{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T02:56:51Z","timestamp":1761101811314},"reference-count":48,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2006,11,1]],"date-time":"2006-11-01T00:00:00Z","timestamp":1162339200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Curr Treat Options Cardio Med"],"published-print":{"date-parts":[[2006,11]]},"DOI":"10.1007\/s11936-006-0035-5","type":"journal-article","created":{"date-parts":[[2007,6,3]],"date-time":"2007-06-03T14:41:36Z","timestamp":1180881696000},"page":"468-473","source":"Crossref","is-referenced-by-count":10,"title":["Current treatment in cardiac amyloidosis"],"prefix":"10.1007","volume":"8","author":[{"given":"Ivana","family":"Kholov\u00e1","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Josef","family":"Kautzner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"35_CR1","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1056\/NEJMra023144","volume":"349","author":"G Merlini","year":"2003","unstructured":"Merlini G, Bellotti V: Molecular mechanisms of amyloidosis. N Engl J Med 2003, 349:583\u2013596.","journal-title":"N Engl J Med"},{"key":"35_CR2","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1136\/jcp.2004.017293","volume":"58","author":"I Kholov\u00e1","year":"2005","unstructured":"Kholov\u00e1 I, Niessen HW: Amyloid in cardiovascular system: a review. J Clin Pathol 2005, 58:125\u2013133.","journal-title":"J Clin Pathol"},{"key":"35_CR3","doi-asserted-by":"crossref","first-page":"197","DOI":"10.3109\/13506120209114823","volume":"9","author":"P Westermark","year":"2002","unstructured":"Westermark P, Benson MD, Buxbaum JN, et al.: Amyloid fibril protein nomenclature\u20142002. Amyloid 2002, 9:197\u2013200.","journal-title":"Amyloid"},{"key":"35_CR4","first-page":"178","volume":"32","author":"W Hassan","year":"2005","unstructured":"Hassan W, Al-Sergani H, Mourad W, Tabbaa R: Amyloid heart disease. New frontiers and insights in pathophysiology, diagnosis, and management. Tex Heart Inst J 2005, 32:178\u2013184.","journal-title":"Tex Heart Inst J"},{"key":"35_CR5","doi-asserted-by":"crossref","first-page":"2047","DOI":"10.1161\/CIRCULATIONAHA.104.489187","volume":"112","author":"RH Falk","year":"2005","unstructured":"Falk RH: Diagnosis and management of the cardiac amyloidoses. Circulation 2005, 112:2047\u20132060.","journal-title":"Circulation"},{"key":"35_CR6","doi-asserted-by":"crossref","first-page":"2091","DOI":"10.1161\/01.CIR.0000034511.06350.DF","volume":"106","author":"C R\u00f6cken","year":"2002","unstructured":"R\u00f6cken C, Peters B, Juenemann G, et al.: Atrial amyloidosis. An arrhythmogenic substrate for persistent atrial fibrillation. Circulation 2002, 106:2091\u20132097.","journal-title":"Circulation"},{"key":"35_CR7","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1007\/s00428-006-0197-2","volume":"449","author":"I Steiner","year":"2006","unstructured":"Steiner I, H\u00e1jkov\u00e1 P, Kvasnicka P, Kholov\u00e1 I: Myocardial sleeves of pulmonary veins and atrial fibrillation: a postmortem histopathological study of 100 subjects. Virchows Arch 2006, 449:88\u201395.","journal-title":"Virchows Arch"},{"key":"35_CR8","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1056\/NEJM199701233360407","volume":"336","author":"SS Kushwaha","year":"1997","unstructured":"Kushwaha SS, Fallon JT, Fuster V: Restrictive cardiomyopathy. N Engl J Med 1997, 336:267\u2013276.","journal-title":"N Engl J Med"},{"key":"35_CR9","doi-asserted-by":"crossref","first-page":"1735","DOI":"10.1378\/chest.120.5.1735","volume":"120","author":"D Dingli","year":"2001","unstructured":"Dingli D, Utz JP, Gertz MA: Pulmonary hypertension in patients with amyloidosis. Chest 2001, 120:1735\u20131738.","journal-title":"Chest"},{"key":"35_CR10","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1097\/00002281-200401000-00013","volume":"16","author":"JN Buxbaum","year":"2004","unstructured":"Buxbaum JN: The systemic amyloidoses. Curr Opin Rheumatol 2004, 16:67\u201375.","journal-title":"Curr Opin Rheumatol"},{"key":"35_CR11","doi-asserted-by":"crossref","first-page":"127","DOI":"10.3109\/13506120309041735","volume":"10","author":"CJ O\u2019Hara","year":"2003","unstructured":"O\u2019Hara CJ, Falk RH: The diagnosis and typing of cardiac amyloidosis. Amyloid 2003, 10:127\u2013129.","journal-title":"Amyloid"},{"key":"35_CR12","doi-asserted-by":"crossref","first-page":"1278","DOI":"10.4065\/77.12.1278","volume":"77","author":"MA Gertz","year":"2002","unstructured":"Gertz MA: Diagnosing primary amyloidosis. Mayo Clin Proc 2002, 77:1278\u20131279.","journal-title":"Mayo Clin Proc"},{"key":"35_CR13","first-page":"20","volume":"63","author":"M Prochorec-Sobieszek","year":"2005","unstructured":"Prochorec-Sobieszek M, Bilinska ZT, Grzybowski J, et al.: Cardiac amyloidosis diagnosed by endomyocardial biopsy. Clinical, histopathological, immunohistochemical and ultrastructural studies. Kardiol Pol 2005, 63:20\u201335.","journal-title":"Kardiol Pol"},{"key":"35_CR14","doi-asserted-by":"crossref","first-page":"2996","DOI":"10.1161\/hc4901.102568","volume":"104","author":"SA Hunt","year":"2001","unstructured":"Hunt SA, Baker DW, Chin MH, et al.: ACC\/AHA guidelines for the evaluation and management of chronic heart failure in the adult: executive summary: a report of the American College of Cardiology\/American Heart Association Task Force on Practice Guidelines (Committee to Revise the 1995 Guidelines for the Evaluation and Management of Heart Failure). Circulation 2001, 104:2996\u20133007.","journal-title":"Circulation"},{"key":"35_CR15","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1309\/TWBM-8L4E-VK22-FRH5","volume":"116","author":"CL Murphy","year":"2001","unstructured":"Murphy CL, Eulitz M, Hrncic R, et al.: Chemical typing of amyloid protein contained in formalin-fixed paraffin-embedded biopsy specimens. Am J Clin Pathol 2001, 116:135\u2013142.","journal-title":"Am J Clin Pathol"},{"key":"35_CR16","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1136\/jcp.56.2.86","volume":"56","author":"B Kaplan","year":"2003","unstructured":"Kaplan B, Shtrasburg S, Pras M: Micropurification techniques in the analysis of amyloid proteins. J Clin Pathol 2003, 56:86\u201390.","journal-title":"J Clin Pathol"},{"key":"35_CR17","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1007\/s00428-003-0834-y","volume":"443","author":"C R\u00f6cken","year":"2003","unstructured":"R\u00f6cken C, Sletten K: Amyloid in surgical pathology. Virchows Arch 2003, 443:3\u201316.","journal-title":"Virchows Arch"},{"key":"35_CR18","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1007\/s11936-005-0029-8","volume":"7","author":"S Parikh","year":"2005","unstructured":"Parikh S, De Lemos JA: Current therapeutic strategies in cardiac amyloidosis. Curr Treat Options Cardiovasc Med 2005, 7:443\u2013448.","journal-title":"Curr Treat Options Cardiovasc Med"},{"key":"35_CR19","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/S0268-960X(03)00027-4","volume":"18","author":"MA Gertz","year":"2004","unstructured":"Gertz MA, Lacy MQ, Dispenzieri A: Therapy for immunoglobulin light chain amyloidosis: the new and the old. Blood Rev 2004, 18:17\u201337. This paper summarizes the treatment of primary amyloidosis and reviews a wide range of clinical trials and studies.","journal-title":"Blood Rev"},{"key":"35_CR20","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1046\/j.1523-1755.2002.00085.x","volume":"61","author":"MA Gertz","year":"2002","unstructured":"Gertz MA, Lacy MQ, Dispenzieri A: Immunoglobulin light chain amyloidosis and the kidney. Kidney Int 2002, 61:1\u20139.","journal-title":"Kidney Int"},{"key":"35_CR21","doi-asserted-by":"crossref","first-page":"1202","DOI":"10.1056\/NEJM199704243361702","volume":"336","author":"RA Kylle","year":"1997","unstructured":"Kylle RA, Gertz MA, Greipp PR, et al.: A trail of three regimens for primary amyloidosis: colchicine alone, melphalan and prednisone and melphalan, prednisone and colchicine. N Engl J Med 1997, 336:1202\u20131207.","journal-title":"N Engl J Med"},{"key":"35_CR22","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1046\/j.1365-2141.2002.03541.x","volume":"117","author":"V Sanchorawala","year":"2002","unstructured":"Sanchorawala V, Wright DG, Seldin DC, et al.: Low-dose continuous oral melphalan for the treatment of primary systemic (AL) amyloidosis. Br J Haematol 2002, 117:886\u2013889.","journal-title":"Br J Haematol"},{"key":"35_CR23","doi-asserted-by":"crossref","first-page":"2936","DOI":"10.1182\/blood-2003-08-2788","volume":"103","author":"G Palladini","year":"2004","unstructured":"Palladini G, Perfetti V, Obici L, et al.: Association of melphalan and high-dose dexamethasone is effective and well tolerated in patients with AL (primary) amyloidosis who are ineligible for stem cell transplantation. Blood 2004, 103:2936\u20132938.","journal-title":"Blood"},{"key":"35_CR24","doi-asserted-by":"crossref","unstructured":"Gertz MA, Merlini G, Treon SP: Amyloidosis and Waldenstrom\u2019s macroglobulinemia. Hematology Am Soc Hematol Educ Program 2004, 257\u2013282.","DOI":"10.1182\/asheducation-2004.1.257"},{"key":"35_CR25","doi-asserted-by":"crossref","first-page":"241","DOI":"10.3816\/CLM.2003.n.005","volume":"3","author":"DC Seldin","year":"2003","unstructured":"Seldin DC, Choufani EB, Dember LM, et al.: Tolerability and efficacy of thalidomide for the treatment of patients with light chain-associated (AL) amyloidosis. Clin Lymphoma 2003, 3:241\u2013246.","journal-title":"Clin Lymphoma"},{"key":"35_CR26","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1056\/NEJMcibr044231","volume":"352","author":"JW Kelly","year":"2005","unstructured":"Kelly JW: Attacking amyloid. N Engl J Med 2005, 352:722\u2013723.","journal-title":"N Engl J Med"},{"key":"35_CR27","doi-asserted-by":"crossref","first-page":"31466","DOI":"10.1074\/jbc.M201308200","volume":"277","author":"Y Avramovich","year":"2002","unstructured":"Avramovich Y, Amit T, Youdim MBH: Non-steroidal anti-inflammatory drugs stimulate secretion of nonamyloidogenic precursor protein. J Biol Chem 2002, 277:31466\u201331773.","journal-title":"J Biol Chem"},{"key":"35_CR28","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1021\/jm010257n","volume":"45","author":"VB Oza","year":"2002","unstructured":"Oza VB, Smith C, Raman P, et al.: Synthesis, structure, and activity of diclofenac analogues as transthyretin amyloid fibril formation inhibitors. J Med Chem 2002, 45:321\u2013332.","journal-title":"J Med Chem"},{"key":"35_CR29","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1038\/labinvest.3700059","volume":"84","author":"SR Miller","year":"2004","unstructured":"Miller SR, Sekijima Y, Kelly JW: Native state stabilization by NSAIDs inhibits transthyretin amyloidogenesis from the most common familial disease variant. Lab Invest 2004, 84:545\u2013552.","journal-title":"Lab Invest"},{"key":"35_CR30","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1136\/heart.85.2.202","volume":"85","author":"SW Dubrey","year":"2001","unstructured":"Dubrey SW, Burke MM, Khaghani A, et al.: Long-term results of heart transplantation in patients with amyloid heart disease. Heart 2001, 85:202\u2013207.","journal-title":"Heart"},{"key":"35_CR31","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.1016\/j.healun.2003.08.027","volume":"23","author":"SW Dubrey","year":"2004","unstructured":"Dubrey SW, Burke MM, Hawkins PN, Banner NR: Cardiac transplantation for amyloid heart disease: the United Kingdom experience. J Heart Lung Transplant 2004, 23:1142\u20131153. This study deals with heart transplantation in cardiac amyloidosis and summarizes the center and literature experience.","journal-title":"J Heart Lung Transplant"},{"key":"35_CR32","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1182\/blood-2005-08-3253","volume":"107","author":"JD Gillmore","year":"2006","unstructured":"Gillmore JD, Goodman HJ, Lachmann HJ, et al.: Sequential heart and autologous stem cell transplantation for systemic AL amyloidosis. Blood 2006, 107:1227\u20131229.","journal-title":"Blood"},{"key":"35_CR33","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1046\/j.1365-2796.2003.01173.x","volume":"254","author":"OB Suhr","year":"2003","unstructured":"Suhr OB, Svendsen IH, Andersson R, et al.: Hereditary transthyretin amyloidosis from a Scandinavian perspective. J Intern Med 2003, 254:225\u2013235.","journal-title":"J Intern Med"},{"key":"35_CR34","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1053\/jlts.2003.50173","volume":"9","author":"GL Grazi","year":"2003","unstructured":"Grazi GL, Cescon M, Salvi F, et al.: Combined heart and liver transplantation for familial amyloidotic neuropathy: considerations from the hepatic point of view. Liver Transpl 2003, 9:986\u2013992.","journal-title":"Liver Transpl"},{"key":"35_CR35","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1097\/00007890-200104150-00026","volume":"71","author":"JD Gillmore","year":"2001","unstructured":"Gillmore JD, Stangou AJ, Tennent GA, et al.: Clinical and biochemical outcome of hepatorenal transplantation for hereditary systemic amyloidosis associated with apolipoprotein AI Gly26Arg. Transplantation 2001, 71:986\u2013992.","journal-title":"Transplantation"},{"key":"35_CR36","doi-asserted-by":"crossref","first-page":"52","DOI":"10.3109\/13506120108993814","volume":"8","author":"E Jonsen","year":"2001","unstructured":"Jonsen E, Suhr OB, Tashima K, Athlin E: Early liver transplantation is essential for familial amyloidotic polyneuropathy patients\u2019quality of life. Amyloid 2001, 8:52\u201357.","journal-title":"Amyloid"},{"key":"35_CR37","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1067\/mtc.2003.151","volume":"125","author":"G Arpesella","year":"2003","unstructured":"Arpesella G, Chiappini B, Marinelli G, et al.: Combined heart and liver transplantation for familial amyloidotic polyneuropathy. J Thorac Cardiovasc Surg 2003, 125:1165\u20131166.","journal-title":"J Thorac Cardiovasc Surg"},{"key":"35_CR38","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1097\/01.TP.0000046526.10003.EC","volume":"75","author":"S Zeldenrust","year":"2003","unstructured":"Zeldenrust S, Gertz M, Uemichi T, et al.: Orthotopic liver transplantation for hereditary fibrinogen amyloidosis. Transplantation 2003, 75:560\u2013561.","journal-title":"Transplantation"},{"key":"35_CR39","doi-asserted-by":"crossref","first-page":"4276","DOI":"10.1182\/blood.V99.12.4276","volume":"99","author":"RL Comenzo","year":"2002","unstructured":"Comenzo RL, Gertz MA: Autologous stem cell transplantation for primary systemic amyloidosis. Blood 2002, 99:4276\u20134282.","journal-title":"Blood"},{"key":"35_CR40","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1016\/S0002-9343(02)01208-1","volume":"113","author":"MA Gertz","year":"2002","unstructured":"Gertz MA, Lacy MQ, Dispenzieri A, et al.: Stem cell transplantation for the management of primary systemic amyloidosis. Am J Med 2002, 113:549\u2013555.","journal-title":"Am J Med"},{"key":"35_CR41","doi-asserted-by":"crossref","first-page":"85","DOI":"10.7326\/0003-4819-140-2-200401200-00008","volume":"140","author":"M Skinner","year":"2004","unstructured":"Skinner M, Sanchorawala V, Seldin DC: High-dose melphalan and autologous stem-cell transplantation in patients with AL amyloidosis: an 8-year study. Ann Intern Med 2004, 140:85\u201393.","journal-title":"Ann Intern Med"},{"key":"35_CR42","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1038\/sj.bmt.1703155","volume":"28","author":"S Kumar","year":"2001","unstructured":"Kumar S, Dispenzieri A, Lacy MQ, et al.: High incidence of gastrointestinal bleeding after autologous stem cell transplant for primary systemic amyloidosis. Bone Marrow Transplant 2001, 28:381\u2013385.","journal-title":"Bone Marrow Transplant"},{"key":"35_CR43","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1002\/ajh.10389","volume":"74","author":"B Oran","year":"2003","unstructured":"Oran B, Wright DG, Seldin DC, et al.: Spontaneous rupture of the spleen in AL amyloidosis. Am J Hematol 2003, 74:131\u2013135.","journal-title":"Am J Hematol"},{"key":"35_CR44","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1038\/sj.bmt.1705112","volume":"36","author":"LQ Chow","year":"2005","unstructured":"Chow LQ, Bahlis N, Russell J, et al.: Autologous transplantation for primary systemic AL amyloidosis is feasible outside a major amyloidosis referral centre: the Calgary BMT Program experience. Bone Marrow Transplant 2005, 36:591\u2013596.","journal-title":"Bone Marrow Transplant"},{"key":"35_CR45","doi-asserted-by":"crossref","first-page":"S160","DOI":"10.1097\/01.tp.0000186902.57687.8d","volume":"80","author":"SO Schonland","year":"2005","unstructured":"Schonland SO, Perz JB, Hundemer M, et al.: Indications for high-dose chemotherapy with autologous stem cell support in patients with systemic amyloid light chain amyloidosis. Transplantation 2005, 80:S160-S163.","journal-title":"Transplantation"},{"key":"35_CR46","doi-asserted-by":"crossref","first-page":"151","DOI":"10.2174\/1389450043490622","volume":"5","author":"S Kolstoe","year":"2004","unstructured":"Kolstoe S, Wood S: Perspectives for drug intervention in amyloid diseases. Curr Drug Targets 2004, 5:151\u2013158.","journal-title":"Curr Drug Targets"},{"key":"35_CR47","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1038\/417254a","volume":"417","author":"MB Pepys","year":"2002","unstructured":"Pepys MB, Herbert J, Hutchinson WL, et al.: Targeted pharmacological depletion of serum amyloid P component for treatment of human amyloidosis. Nature 2002, 417:254\u2013259.","journal-title":"Nature"},{"key":"35_CR48","doi-asserted-by":"crossref","first-page":"4039","DOI":"10.4049\/jimmunol.169.7.4039","volume":"169","author":"S Ohno","year":"2002","unstructured":"Ohno S, Yoshimoto M, Honda S, et al.: The antisense approach in amyloid light chain amyloidosis: identification of monoclonal Ig and inhibition of its production by antisense oligonucleotides in in vitro and in vivo models. J Immunol 2002, 169:4039\u20134045.","journal-title":"J Immunol"}],"container-title":["Current Treatment Options in Cardiovascular Medicine"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11936-006-0035-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11936-006-0035-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11936-006-0035-5","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,6,1]],"date-time":"2019-06-01T20:56:30Z","timestamp":1559422590000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11936-006-0035-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,11]]},"references-count":48,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2006,11]]}},"alternative-id":["35"],"URL":"https:\/\/doi.org\/10.1007\/s11936-006-0035-5","relation":{},"ISSN":["1092-8464","1534-3189"],"issn-type":[{"value":"1092-8464","type":"print"},{"value":"1534-3189","type":"electronic"}],"subject":[],"published":{"date-parts":[[2006,11]]}}}